Genetic assay is predictive of prognosis for kidney cancer
the ONA take:
Researchers in Singapore have developed a test that has the potential to improve treatment of patients with clear cell renal cell carcinoma (ccRCC). ccRCC is the most common type of kidney cancer.
Treatment options include surgery to remove the tumor and tyrosine kinase inhibitor (TKI) therapy. Prognosis for patients, however, is difficult to predict because outcomes vary. This new test identifies genetic markers of different ccRCC subtypes.
In developing this test, the researchers identified eight genes whose expression levels differed between two subtypes of the disease.
Furthermore, the expression profiles of the eight genes proved to reliably predict good or poor prognosis in patients with ccRCC who received TKI therapy as well as underwent surgery.
The researchers report that the assay could be used as a tool to improve surveillance strategies for patients with ccRCC, but clinical trials are needed to determine the assay’s value in relation to various therapies.
A test that has the potential to improve treatment of patients with clear cell renal cell carcinoma.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Travel Distance to Prostate Cancer Treatment Influences Treatment Choice
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|